in-Vitro Toxicology Testing Global Market Report 2024

The core products within in-vitro toxicology testing comprise consumables, assays, equipment, software, and services. Consumables encompass various products utilized in laboratory testing procedures, including items like cannulas and lancets for compound analysis. The methods employed consist of cellular assays, biochemical assays, in silico models, and ex vivo models, employing technologies such as cell culture and high-throughput methodologies. These techniques are applied across various applications, encompassing neurotoxicity, dermal toxicity, cytotoxicity, and other related domains. The industry verticals served include pharmaceuticals, biopharmaceuticals, cosmetics, household products, food, and chemicals.

This report provides in-vitro toxicology testing market statistics, including in-vitro toxicology testing industry global market size, regional shares, competitors with an in-vitro toxicology testing market share, detailed in-vitro toxicology testing market segments, market trends and opportunities, and any further data you may need to thrive in the in-vitro toxicology testing industry. This in-vitro toxicology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The global in-vitro toxicology testing market has grown rapidly in recent years. It will grow from $10.31 billion in 2023 to $11.46 billion in 2024 at a compound annual growth rate (CAGR) of 11.1%. The expansion observed in the historical period can be attributed to regulatory mandates, ethical considerations regarding animal welfare, cost and time efficiency, the globalization of the pharmaceutical industry, demands in drug discovery and development, and heightened public awareness concerning environmental toxins.

The global in-vitro toxicology testing market is expected to see rapid growth in the next few years. It will grow to $17.13 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. Anticipated growth in the upcoming period is driven by a heightened emphasis on personalized medicine, increased demand for predictive toxicology models, the expansion of environmental testing, challenges encountered in oncology drug development, and a focused approach toward endocrine disruptor screening. Key trends expected in this period encompass advancements in 3D cell culture technologies, the integration of high-throughput screening methodologies, a concentrated effort on organ-on-a-chip technologies, applications in chemical safety assessment, utilization of human-derived cell lines, incorporation of omics technologies, and the implementation of educational initiatives and training programs.

Anticipated growth in the in-vitro toxicology testing market is attributed to the escalating healthcare expenditure worldwide. This expenditure refers to the money allocated from individuals and government budgets towards hospitals, prescription drugs, nursing facilities, and healthcare services. A March 2022 report by the Centers for Medicare & Medicaid Services projected a steady annual increase of 5.1% in national health spending between 2021 and 2030, reaching approximately $6.8 trillion. Within this, Medicare spending is expected to rise at a 7.2% annual pace, while Medicaid spending is estimated to increase at a 5.6% annual rate. This upward trend in healthcare expenditure fuels the demand for in-vitro toxicology testing due to the growing prevalence of diseases.

The in-vitro toxicology testing market is set to experience a boost owing to the expanding pharmaceutical industry. This sector, responsible for researching, developing, producing, and marketing pharmaceutical drugs, is witnessing an increased demand for in-vitro toxicology testing services. These services play a critical role in screening new drug candidates and ensuring the safety of existing products. A March 2022 report by Atradius revealed that the US pharmaceutical market represents roughly 45% of the global market and contributes to 22% of the world's production, signifying significant growth potential in driving the demand for in-vitro toxicology testing within this industry.

A prominent trend in the in-vitro toxicology market is the development of innovative cell culture systems. Key players in this market are focused on pioneering technological solutions to solidify their positions. For instance, in August 2021, Amerigo Scientific, operating in the in-vitro toxicology testing realm, introduced cutting-edge vitro 3D cell culture technology. This innovative solution, facilitating precision medicine approaches, accommodates human and animal cells, offering a viable alternative that reduces small animal studies in drug development, aligning with ethical and economic considerations.

Major companies in the in-vitro toxicology testing market are adopting strategic partnership approaches to deliver 3D in-vitro services to various stakeholders. Strategic partnerships involve leveraging mutual strengths and resources for collective benefits and success. In January 2021, Charles River, a US-based provider of pharmaceutical products and services, collaborated with Cypre Inc., a biotechnology company. This collaboration enables Charles River to offer Cypre's exclusive 3D tumor model platform, Falcon, to its clients, enhancing the company's 3D in-vitro testing capabilities, specifically in immuno-oncology. Utilizing proprietary techniques, including Cypre's patented 3D hydrogel patterning technology, the platform replicates tumor microenvironments, facilitating predictive screening of novel immuno-oncology drugs.
In December 2021, Aragen Life Sciences Private Limited, an R&D and manufacturing solutions provider based in India, successfully acquired Intox Private Limited for an undisclosed sum. This strategic acquisition serves to broaden Aragen's offerings in integrated drug discovery and development toxicology services specifically catered to pharmaceutical companies. Intox Private Limited, another India-based entity, specializes in in-vitro toxicology testing and was the target of this acquisition by Aragen Life Sciences.

Major companies operating in the in-vitro toxicology testing market report are Thermo Fisher Scientific Inc., Merck KGaA, Laboratory Corporation of America Holdings (LabCorp), Gentronix Limited (a subsidiary of Eurofins Scientific SE), Bio-Rad Laboratories Inc., Eurofins Scientific SE, Charles River Laboratories International Inc., Promega Corporation, Agilent Technologies Inc., Abbott Laboratories, Evotec SE, SGS SA, BioIVT LLC, MB Research Laboratories LLC, Creative Biolabs Inc., Quest Diagnostics Incorporated, Creative Bioarray Inc., InSphero AG, PerkinElmer Inc., Cyprotex PLC, MatTek Corporation, Danaher Corporation, Ncardia AG, Sekisui Chemical Co. Ltd., BioReliance Corporation, CellSystems Biotechnologie Vertrieb GmbH, Taconic Biosciences Inc., Biopredic International, MultiCell Technologies Inc., Altasciences Clinical Research Holdings Inc., Molecular Toxicology Inc., Toxys BV, XenoTech LLC, Optivia Biotechnology Inc., Toxikon Corporation

North America was the largest region in the in- vitro toxicology testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the in- vitro toxicology testing market report during the forecast period. The regions covered in the in-vitro toxicology testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the in-vitro toxicology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The in-vitro toxicology testing market includes revenues earned by entities by providing metabolic, toxicokinetic, and bioanalytical investigations. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.